|
EUR million |
Used for |
2011 |
2010 |
Change % |
| Stalevo®, Comtess® / Comtan® |
Parkinson's disease |
266.7 |
252.7 |
+5.5% |
| Simdax® |
acute decompensated heart failure |
44.0 |
39.9 |
+10.4% |
| Precedex® |
intensive care sedative |
33.0 |
27.2 |
+21.3% |
| Easyhaler® product family |
asthma, COPD |
30.5 |
28.1 |
+8.6% |
| Burana® |
inflammatory pain |
23.5 |
21.5 |
+9.2% |
| Domitor®, Dexdomitor®, Domosedan® and Antisedan® |
animal sedatives |
23.2 |
24.2 |
-3.9% |
| Marevan® |
anticoagulant |
15.6 |
13.1 |
+19.5% |
| Divina® product range |
menopausal symptoms |
13.2 |
13.3 |
-0.7% |
| Enanton® |
prostate cancer |
12.0 |
13.0 |
-7.7% |
| Solomet® |
inflammatory diseases |
10.7 |
8.6 |
+24.8% |
| Total |
|
472.4 |
441.5 |
+7.0% |
Share of pharmaceutical net
sales, % |
|
54% |
55% |
|